Used primarily as a key intermediate in the synthesis of Apremilast, a selective phosphodiesterase 4 (PDE4) inhibitor for treating inflammatory conditions such as plaque psoriasis and psoriatic arthritis. Its structure enables modulation of cyclic AMP levels, leading to reduced production of pro-inflammatory cytokines like TNF-α, IL-17, and IL-23. The 4-amino group allows for further derivatization, such as acetylation, to enhance the compound's pharmacological properties and selectivity. It is also utilized in research to develop novel small-molecule therapeutics targeting inflammatory pathways.